163 related articles for article (PubMed ID: 2401562)
1. Characterization of Leishmania major antigen-liposomes that protect BALB/c mice against cutaneous leishmaniasis.
Kahl LP; Lelchuk R; Scott CA; Beesley J
Infect Immun; 1990 Oct; 58(10):3233-41. PubMed ID: 2401562
[TBL] [Abstract][Full Text] [Related]
2. Vaccination against murine cutaneous leishmaniasis by using Leishmania major antigen/liposomes. Optimization and assessment of the requirement for intravenous immunization.
Kahl LP; Scott CA; Lelchuk R; Gregoriadis G; Liew FY
J Immunol; 1989 Jun; 142(12):4441-9. PubMed ID: 2786033
[TBL] [Abstract][Full Text] [Related]
3. The role of liposome charge on immune response generated in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63).
Badiee A; Jaafari MR; Khamesipour A; Samiei A; Soroush D; Kheiri MT; Barkhordari F; McMaster WR; Mahboudi F
Exp Parasitol; 2009 Apr; 121(4):362-9. PubMed ID: 19211022
[TBL] [Abstract][Full Text] [Related]
4. Characterization of Leishmania donovani antigens encapsulated in liposomes that induce protective immunity in BALB/c mice.
Afrin F; Rajesh R; Anam K; Gopinath M; Pal S; Ali N
Infect Immun; 2002 Dec; 70(12):6697-706. PubMed ID: 12438344
[TBL] [Abstract][Full Text] [Related]
5. gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani.
Bhowmick S; Ravindran R; Ali N
Infect Immun; 2008 Mar; 76(3):1003-15. PubMed ID: 18195029
[TBL] [Abstract][Full Text] [Related]
6. Effective immunization against cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes.
Russell DG; Alexander J
J Immunol; 1988 Feb; 140(4):1274-9. PubMed ID: 3257774
[TBL] [Abstract][Full Text] [Related]
7. Leishmania major: production of recombinant gp63, its antigenicity and immunogenicity in mice.
Handman E; Button LL; McMaster RW
Exp Parasitol; 1990 May; 70(4):427-35. PubMed ID: 2182337
[TBL] [Abstract][Full Text] [Related]
8. Identification and characterization of host-protective T-cell epitopes of a major surface glycoprotein (gp63) from Leishmania major.
Yang DM; Rogers MV; Liew FY
Immunology; 1991 Jan; 72(1):3-9. PubMed ID: 1997399
[TBL] [Abstract][Full Text] [Related]
9. Vaccination against cutaneous leishmaniasis in a murine model. I. Induction of protective immunity with a soluble extract of promastigotes.
Scott P; Pearce E; Natovitz P; Sher A
J Immunol; 1987 Jul; 139(1):221-7. PubMed ID: 3495599
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of immune response and protection in BALB/c mice immunized with liposomal recombinant major surface glycoprotein of Leishmania (rgp63): the role of bilayer composition.
Badiee A; Jaafari MR; Khamesipour A; Samiei A; Soroush D; Kheiri MT; Barkhordari F; McMaster WR; Mahboudi F
Colloids Surf B Biointerfaces; 2009 Nov; 74(1):37-44. PubMed ID: 19615870
[TBL] [Abstract][Full Text] [Related]
11. Immunization of susceptible hosts with a soluble antigen fraction from Leishmania major leads to aggravation of murine leishmaniasis mediated by CD4+ T cells.
Bogdan C; Schröppel K; Lohoff M; Röllinghoff M; Solbach W
Eur J Immunol; 1990 Dec; 20(12):2533-40. PubMed ID: 1980108
[TBL] [Abstract][Full Text] [Related]
12. Leishmania major: immune response in BALB/c mice immunized with stress-inducible protein 1 encapsulated in liposomes.
Badiee A; Jaafari MR; Khamesipour A
Exp Parasitol; 2007 Feb; 115(2):127-34. PubMed ID: 16979165
[TBL] [Abstract][Full Text] [Related]
13. The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome.
Jaafari MR; Badiee A; Khamesipour A; Samiei A; Soroush D; Kheiri MT; Barkhordari F; McMaster WR; Mahboudi F
Vaccine; 2007 Aug; 25(32):6107-17. PubMed ID: 17629372
[TBL] [Abstract][Full Text] [Related]
14. Transcutaneous immunization using SLA or rLACK skews the immune response towards a Th1 profile but fails to protect BALB/c mice against a Leishmania major challenge.
Lakhal-Naouar I; Koles N; Rao M; Morrison EB; Childs JM; Alving CR; Aronson NE
Vaccine; 2019 Jan; 37(3):516-523. PubMed ID: 30528328
[TBL] [Abstract][Full Text] [Related]
15. Susceptibility to murine cutaneous leishmaniasis correlates with the capacity to generate interleukin 3 in response to leishmania antigen in vitro.
Lelchuk R; Graveley R; Liew FY
Cell Immunol; 1988 Jan; 111(1):66-76. PubMed ID: 3257416
[TBL] [Abstract][Full Text] [Related]
16. Comparison of liposome based antigen delivery systems for protection against Leishmania donovani.
Bhowmick S; Mazumdar T; Sinha R; Ali N
J Control Release; 2010 Jan; 141(2):199-207. PubMed ID: 19818373
[TBL] [Abstract][Full Text] [Related]
17. Protection of mice against visceral leishmaniasis by immunization with promastigote antigen incorporated in liposomes.
Ali N; Afrin F
J Parasitol; 1997 Feb; 83(1):70-5. PubMed ID: 9057699
[TBL] [Abstract][Full Text] [Related]
18. Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized Th1 response.
Bhowmick S; Ravindran R; Ali N
Vaccine; 2007 Aug; 25(35):6544-56. PubMed ID: 17655984
[TBL] [Abstract][Full Text] [Related]
19. Immunoliposomes containing Soluble Leishmania Antigens (SLA) as a novel antigen delivery system in murine model of leishmaniasis.
Eskandari F; Talesh GA; Parooie M; Jaafari MR; Khamesipour A; Saberi Z; Abbasi A; Badiee A
Exp Parasitol; 2014 Nov; 146():78-86. PubMed ID: 25246326
[TBL] [Abstract][Full Text] [Related]
20. Induction of protection against leishmaniasis in susceptible BALB/c mice using simple DOTAP cationic nanoliposomes containing soluble Leishmania antigen (SLA).
Firouzmand H; Badiee A; Khamesipour A; Heravi Shargh V; Alavizadeh SH; Abbasi A; Jaafari MR
Acta Trop; 2013 Dec; 128(3):528-35. PubMed ID: 23916506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
